IRF2 and hepatocellular carcinoma: Interestingly, expression of IRF2 and POU2F1 target genes in TCGA-LIHC cohort were notably downregulated in HCC patients with either CTNNB1, AXIN1, or APC mutations compared to those that did not have mutations known to confer β-catenin activation (Figure 5d).